GT Biopharma is making moves! They’re gearing up for a 2026 trial of their new cancer treatment, GTB-5550 TriKE, which targets tough solid tumors. This is their third NK cell engager headed for clinical development. The trial will test different doses and could be a game-changer for patients with B7-H3-expressing cancers. Plus, their stock just jumped nearly 13%—investors are definitely watching! #Health #BodyHealth #CancerResearch